SEC Contract Filing

Filing Date: 2025-04-30

Document Content:
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ef20048125_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<html>
 <head>
 <title></title>
 <!-- Licensed to: Broadridge
 Document created using Broadridge PROfile 25.3.2.5298
 Copyright 1995 - 2025 Broadridge -->
 </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
 <div>
 <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
 <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 10.1</font><br>
 </div>
 <div> <br>
 </div>
 <div>
 <div style="text-align: center; font-weight: bold;"> <font style="font-family: 'Times New Roman';">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL
 AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font><br>
 </div>
 <div style="text-align: center; font-weight: bold;"><font style="font-family: 'Times New Roman';"> <br>
 </font></div>
 <div style="text-align: center; font-weight: bold;">Separation Agreement and Release</div>
 <div>&#160;</div>
 <div style="text-align: justify; text-indent: 36pt;">This Separation Agreement and Release (&#8220;<u>Agreement</u>&#8221;) is made by and between <font style="color: #000000;">Sahil Kirpekar</font> (&#8220;<u>Executive</u>&#8221;) and ATAI Life Sciences US, Inc., a
 Delaware corporation (together with any successor, the &#8220;<u>Company</u>&#8221;) (collectively referred to as the &#8220;<u>Parties</u>&#8221; or individually referred to as a &#8220;<u>Party</u>&#8221;).&#160; Capitalized terms used but not defined in this Agreement shall have the
 meanings set forth in the Employment Agreement (as defined below).</div>
 <div>&#160;</div>
 <div style="text-align: justify; text-indent: 36pt;">WHEREAS, in connection with Executive&#8217;s termination of employment with the Company or a subsidiary or affiliate of the Company effective April 2, 2025, the Parties wish to resolve any and all
 disputes, claims, complaints, grievances, charges, actions, petitions, and demands that Executive may have against the Company and any of the Releases as defined below, including, but not limited to, any and all claims arising out of or in any way
 related to Executive&#8217;s employment with or separation from the Company or its subsidiaries or affiliates but, for the avoidance of doubt, nothing herein will be deemed to release any rights or remedies in connection with Executive&#8217;s ownership of
 vested equity securities of the Company or one if its affiliates, vested benefits or Executive&#8217;s right to indemnification by the Company or any of its affiliates pursuant to contract or applicable law (collectively, the &#8220;<u>Retained Claims</u>&#8221;).</div>
 <div>&#160;</div>
 <div style="text-align: justify; text-indent: 36pt;">NOW, THEREFORE, in consideration of the severance payments and benefits described in Section 7(b) of the Employment Agreement, which, pursuant to the Employment Agreement, are conditioned on
 Executive&#8217;s execution and non-revocation of this Agreement, and in consideration of the mutual promises made herein, the Company and Executive hereby agree as follows:</div>
 <div>&#160;</div>
 <div style="text-align: justify; text-indent: 36pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Severance Payments and Benefits; Salary and Benefits</u>.&#160; The Company agrees to provide Executive with the severance payments and benefits described in Section 7(b) of the
 Employment Agreement, payable at the times set forth in, and subject to the terms and conditions of, the Employment Agreement and Executive&#8217;s continued compliance with the Confidentiality and Developments Agreement dated November 29, 2022 (the
 &#8220;CADA&#8221;). In addition, to the extent not already paid, and subject to the terms and conditions of the Employment Agreement, the Company shall pay or provide to Executive all other payments or benefits described in Section 6(c) of the Employment
 Agreement, subject to and in accordance with the terms thereof. <font style="color: rgb(0, 0, 0);">In addition, if Executive becomes entitled to the&#160;employment agreement severance payments, Executive will also be entitled to the additional
 severance benefits set forth in (A)-(E):</font></div>
 <div>&#160;</div>
 <table cellspacing="0" cellpadding="0" id="z1fffe48ebb7a445bad0e62890bdbba49" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

 <tr>
 <td style="width: 72pt;"><br>
 </td>
 <td style="width: 18pt; vertical-align: top;">A.</td>
 <td style="width: auto; vertical-align: top; text-align: justify;">
 <div><font style="font-style: italic;">Legal Fees</font>. Reimbursement of reasonable legal fees to review and prepare this agreement, up to a five-thousand dollar ($5,000.00) cap, paid within thirty (30) days of submission, which submission
 shall be made no later than April 30, 2025;</div>
 </td>
 </tr>

 </table>
 <div>&#160;</div>
 <table cellspacing="0" cellpadding="0" id="zdf7282ef1d2f4203abf0d3152e735a4e" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

 <tr>
 <td style="width: 72pt;"><br>
 </td>
 <td style="width: 18pt; vertical-align: top;">B.</td>
 <td style="width: auto; vertical-align: top; text-align: justify;">
 <div><font style="font-style: italic;">Option Exercise Extension</font>. Extension of the post-termination exercise window for Executive&#8217;s vested options to purchase ATAI Life Sciences, N.V. common shares set forth in the applicable option
 agreement until August 14, 2025, subject to approval of the Management Board of&#160; ATAI Life Sciences N.V., and su